S&P/ASX All Ords Index (ASX: XAO) shares are up 0.34% to 8,889.5 points on Tuesday.

Over 12 months, the market is down 4.21%.

The US-Iran war, high oil prices, rising interest rates, and multi-decade-high bond yields are weighing on share price valuations.

However, experts say there are buying opportunities amid today’s turbulent trading conditions.

Let’s check them out. 

CAR Group Ltd (ASX: CAR)

The CAR share price is $22.02, down 0.23% today and down 43% over 12 months. 

Arthur Garipoli from Dolphin Partners has a buy rating on this ASX consumer discretionary share. 

Garipoli said (courtesy The Bull):

This online automotive platform operator recently posted a solid fiscal year 2026 result.

Reported revenue of $A1.253 billion was up 6 per cent on the prior corresponding period. Reported net profit after tax of $A314 million was up 14 per cent.

The stock has fallen on AI disruption concerns. At recent levels, the stock screens favourably on a risk adjusted returns basis.

The company expects to generate high single digit revenue growth in Australia in fiscal year 2027 and double digit revenue growth in constant currency in North America and Latin America.

Global Lithium Resources Ltd (ASX: GL1)

The Global Lithium Resources share price is $1.01, up 1.51% today and up 181% over 12 months. 

Shaw & Partners has a buy recommendation on this ASX lithium share. 

The broker has a 12-month share price target of $1.75 on Global Lithium Resources shares.

In a new note, Shaw & Partners said: 

Global Lithium Resources Limited (ASX: GL1) has released its Manna-Nova Integration Study, the first quantified assessment of a streamlined development pathway that treats Manna ore at the recently acquired Nova processing plant.

By utilising Nova’s existing infrastructure ($7m acquisition) via a 135km haul route, GL1 avoids the $440m greenfield concentrator build proposed in the Dec’25 DFS.

Integrating targeted process additions onto Nova’s established brownfield foundation significantly reduces upfront capital requirements, de-risks project delivery, and accelerates the timeline to first cash flow.

Netwealth Group Ltd (ASX: NWL)

The Netwealth share price is $17.03, down 0.76% today and down 44% over 12 months. 

In a new note, Bell Potter retained its buy call on this ASX financial share. 

However, the broker reduced its 12-month share price target from $30 to $25.

Bell Potter said: 

Maintain Buy. Given interest rates,we have moved our valuation multiple to 2022-23 levels with a class action provision.

Our flow expectations are below FY27 guidance.

NWL has operated in similar environments,with large withdrawals and clients moving off platform.

FY23 flows landed -10% below the guidance and growth was restored in 12mths.

Our $17.9bn matches this experience. So far, we are 6mths into the cycle.

The post 3 ASX shares to buy amid a volatile market: experts appeared first on The Motley Fool Australia.

More reading

• CAR Group vs Seek: Which ASX 200 stock is better value?
• Buy, hold, sell: Myer, Develop Global, Netwealth shares
• Top brokers name 3 ASX shares to buy next week
• Top ASX shares to buy in October 2026
• This ASX 200 share is tipped to return over 50%

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Netwealth Group. The Motley Fool Australia has positions in and has recommended Netwealth Group. The Motley Fool Australia has recommended CAR Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Vanguard MSCI Index International Shares ETF (ASX: VGS) and Vanguard S&P 500 US Shares Index ETF (ASX: V500) are two Vanguard exchange-traded funds (ETFs) I would happily own for the long term.

There is also plenty of overlap between them, which can make choosing between the two less straightforward than it first appears.

So, if I could buy only one, which would get my money?

Why buy the VGS ETF?

The VGS ETF is the broader option. It gives investors exposure to around 1,300 stocks across approximately 23 developed countries outside Australia, including the United States, Japan, the UK, Canada, France, and Switzerland.

That geographic spread is its biggest strength, in my view. The US still accounts for a large part of the portfolio, so investors retain significant exposure to companies such as NVIDIA, Apple, and Microsoft. But the VGS ETF also puts money to work across other developed economies.

That could prove valuable during periods when US shares are not leading global markets. Rather than needing to predict which country performs best next, investors have exposure across a much wider group.

For someone wanting a single international ETF to provide broad diversification, I think the Vanguard MSCI Index International Shares ETF is difficult to fault.

What does the V500 ETF do differently?

The V500 ETF focuses entirely on the United States. It tracks the famous S&P 500 Index (SP: .INX), giving investors exposure to around 500 large US companies representing roughly 80% of the value of the American share market.

Many of the largest companies are also owned by the VGS ETF. NVIDIA, Apple, Microsoft, Amazon, and Alphabet currently sit at the top of the portfolio.

The difference is how much influence these US businesses have. The V500 ETF does not dilute that exposure with Japanese, European, Canadian, or other developed-market companies. Investors are making a clearer bet that the US can continue producing some of the world’s strongest businesses.

I am comfortable with that. The US remains a major centre for artificial intelligence (AI), cloud computing, software, healthcare innovation, consumer brands, and many other industries. The S&P 500 Index also extends well beyond technology, so buying this Vanguard ETF is not simply a bet on a handful of AI companies.

Which Vanguard ETF would I choose?

I would lean towards the V500 ETF. Both funds are buys in my view, and the VGS ETF would actually win if broader geographic diversification were my main priority.

But if I could choose only one, I would prefer to put more weight behind the US businesses inside the Vanguard S&P 500 US Shares Index ETF.

Foolish takeaway

I can see a strong case for owning either ETF.

But for me, the V500 ETF narrowly comes out ahead. I am comfortable accepting less geographic diversification in exchange for greater exposure to the US market.

If I were choosing just one today, it is the Vanguard ETF that would get my money.

The post VGS vs V500: Which Vanguard ETF would I buy? appeared first on The Motley Fool Australia.

More reading

• My top 3 Vanguard ETFs for October
• How much do I need to retire on $110,000 a year at 65?
• VGS vs IVV: Which ETF would I buy with $10,000?
• How I’d build a $50,000 ASX share portfolio today
• Own VAS, VHY, VGS, or other Vanguard ETFs? Here’s your next dividend

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Alphabet, Amazon, Apple, Microsoft, and Nvidia. The Motley Fool Australia has recommended Alphabet, Amazon, Apple, Microsoft, Nvidia, and Vanguard Msci Index International Shares ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares have climbed higher into the green in Tuesday lunchtime trade.

At the time of writing, the ASX biotech stock is up around 1% and is trading for $178.34 a piece.

Today’s increase means CSL shares have now jumped 93% from a 10-year low, recorded in June. The shares have also recouped losses shed this year, and are now up around 4% for the year to date. CSL shares are currently trading 13% lower than this time last year.

What drove the CSL share price rebound?

It looks like a combination of factors drove a renewal of investor confidence.

The company has faced several strong headwinds over the past 18 months, including a general investor rotation away from ASX healthcare shares, a full-year guidance downgrade earlier in the year, and news that the company expects an additional non-cash pre-tax impairment of around $5 million in FY26 and FY27.

But it looks like investors realised that the sell-off was way overdone, and by June the shares were trading significantly below fair value.

CSL’s final FY26 result in mid-August helped drive confidence higher again. The company reported total revenue of US$15.8 billion and NPAT of US$2.6 billion, which came in way ahead of guidance. 

Management described FY26 as a ‘reset year’, and said that in FY27 it expects a return to growth.

And all this has happened while the Australian healthcare sector stages a significant recovery, with investors becoming interested in the sector once again.

And why are the shares climbing higher again today?

Just yesterday, the company announced it has entered into an exclusive deal with Alentis Therapeutics for lixudebart, a treatment targeting rare kidney and liver conditions.

The company plans to expand clinical trials to cover other rare diseases such as focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC), supporting the growth of CSL’s nephrology portfolio.

CSL is expected to make an initial upfront payment of US$355 million to Alentis Therapeutics. It will also make additional commercial milestone payments of up to US$1.2 billion depending on commercial success.

The agreement is valued at up to US$1.6 billion in total.

Is the ASX biotech stock a buy, sell, or hold for October?

It looks like the company is well positioned for future growth. And the experts are bullish that CSL shares can keep climbing higher, too.

Market Index data shows that the majority of brokers have a buy rating on CSL shares. But after the strong rebound over the past couple of months, the average $159.86 target price now implies a downside of around 10% from the current trading level.

Analysts on TradingView are also bullish. Again the majority (11 out of 19) have a buy or strong buy rating on the shares. The average $185.96 target price implies a potential 4% upside, at the time of writing. Some think the shares have the potential to jump another 22% to $218.30 within the next 12 months.

If analyst forecasts are correct, now could be a great time to buy the shares, ahead of the next rally.

The post CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October? appeared first on The Motley Fool Australia.

More reading

• Are CSL shares a buy after its big news?
• CSL unveils exclusive Alentis deal to advance rare disease treatments
• Top ASX shares to buy in October 2026
• CSL vs Pro Medicus: Which ASX healthcare share is better?
• Expert names Woodside and CSL shares as top buys today

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.